Indivior Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Indivior Pharmaceuticals, Inc. (INDV) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $33.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-02-26
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $33.00M.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$2.00M, a 300.00% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $1.00M.
- Indivior Pharmaceuticals, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2022 was -$2.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | $33.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$2.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$2.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |